Overview

Tranexamic Acid During Colonic Endoscopic Resection Procedures

Status:
Not yet recruiting

Trial end date:
2024-10-01

Target enrollment:
0

Participant gender:
All

Summary

Colonoscopy with polypectomy reduces the incidence and mortality associated with colon cancer. However, polypectomy is associated with adverse events such as bleeding. Tranexamic acid (TXA) is a synthetic derivative of lysine that exerts antifibrinolytic effects and may prevent bleeding. The investigators aim to evaluate the effect of local TXA on preventing intraprocedural and postprocedural bleeding in patients undergoing endoscopic mucosal resection (EMR) of large colon polyps.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Assaf-Harofeh Medical Center

Treatments:

Epinephrine
Tranexamic Acid

Criteria

Inclusion Criteria:

- Patients referred for endoscopic resection of non-neoplastic and neoplastic lesions in
the colon presenting to our tertiary academic center.

- Age > 18 years

Exclusion Criteria:

- patients with histories of allergic reactions to TXA

- history of seizures

- pregnancy